CU22585A1 - Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. - Google Patents

Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.

Info

Publication number
CU22585A1
CU22585A1 CU1995122A CU1995122A CU22585A1 CU 22585 A1 CU22585 A1 CU 22585A1 CU 1995122 A CU1995122 A CU 1995122A CU 1995122 A CU1995122 A CU 1995122A CU 22585 A1 CU22585 A1 CU 22585A1
Authority
CU
Cuba
Prior art keywords
idiotypic
immune response
immunotherapy
autoimmune
monoclonal antibodies
Prior art date
Application number
CU1995122A
Other languages
English (en)
Inventor
Marichal Orlando Pena
Zamora Mercedes Ramos
Lopez Gumersinda Bombino
Obaya Teresita Rodriguez
Abraham Amparo Emilia Macias
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU1995122A priority Critical patent/CU22585A1/es
Priority to KR1019970704892A priority patent/KR19980701501A/ko
Priority to CN96192089A priority patent/CN1175958A/zh
Priority to PCT/CU1996/000003 priority patent/WO1997019113A2/es
Priority to AU76904/96A priority patent/AU719369B2/en
Priority to EP96939804A priority patent/EP0820472A1/en
Priority to BR9606978A priority patent/BR9606978A/pt
Priority to CA002210705A priority patent/CA2210705A1/en
Priority to JP9519266A priority patent/JPH11505131A/ja
Priority to US08/875,706 priority patent/US6433148B1/en
Priority to MXPA/A/1997/005444A priority patent/MXPA97005444A/es
Publication of CU22585A1 publication Critical patent/CU22585A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con la rama de la Inmunología y en particular con la selección y uso de (de anticuerpos monoclonales (AcM) antiidiotipos (AB2) de tipo IgG, que poseen la característica de presentar una alta conectividad idiotípica y reconocimiento de los linfocitos B y T humanos, moléculas que de manera esencial participan en el desarrollo de la respuesta inmune. De acuerdo con lo expuesto, el objeto de esta invención es proporcionar AcMs antiidiotipos (AB2) de tipo IgG conectados a la red inmune, capaces de interactuar con los linfocitos B y T y ejercer un efecto inmunoregulador ya sea estimulador y/o supresor de la respuesta inmune, que puedan ser utilizados en la inmunoterapia de las enfermedades autoinmunes, infecciosas y cáncer. La esencia de la invención consiste en seleccionar AcMs antiidiotipos (AB2) de tipo IgG conectados idiotípicamente a la red inmune, capaces de reconocer linfocitos B y T humanos, demostrar el efecto biológico producido en diferentes modelos experimentales de ratones y otras especies de mamíferos con dichos anticuerpos y en la inmunoterapia de las enfermedades autoinmunes, infecciosas y cáncer aquellos que "in vivo" sean capaces de ejercer un efecto inmunoregulador del sistema inmune. La presente invención pudiera tener una amplia aplicación en el campo de la inmunoterapia y en particular en el tratamiento de enfermedades autoinmunes, infecciosas y neoplasias malignas.
CU1995122A 1995-11-17 1995-11-17 Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. CU22585A1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU1995122A CU22585A1 (es) 1995-11-17 1995-11-17 Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
KR1019970704892A KR19980701501A (ko) 1995-11-17 1996-11-18 모노클로널 항치매 항체 및 그 사용
CN96192089A CN1175958A (zh) 1995-11-17 1996-11-18 单克隆抗独特型抗体(ab2)和其用途
PCT/CU1996/000003 WO1997019113A2 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales antiidiotipos (ab2) y sus usos
AU76904/96A AU719369B2 (en) 1995-11-17 1996-11-18 Monoclonal antiidiotypic antibodies (AB2) and their uses
EP96939804A EP0820472A1 (en) 1995-11-17 1996-11-18 Monoclonal antiidiotypic antibodies (ab2) and uses thereof
BR9606978A BR9606978A (pt) 1995-11-17 1996-11-18 Anticorpos monoclonais antiidiótipos (ab2) e usos dos mesmos
CA002210705A CA2210705A1 (en) 1995-11-17 1996-11-18 Monoclonal antiidiotypic antibodies (ab2) and their uses
JP9519266A JPH11505131A (ja) 1995-11-17 1996-11-18 単クローン抗イデイオタイプ抗体（ａｂ２）及びその使用
US08/875,706 US6433148B1 (en) 1995-11-17 1996-11-18 Monoclonal anti-idiotypic antibodies (AB2) and their uses
MXPA/A/1997/005444A MXPA97005444A (es) 1995-11-17 1997-07-17 Anticuerpos monoclonales antidiotipos (ab2) y sususos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1995122A CU22585A1 (es) 1995-11-17 1995-11-17 Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.

Publications (1)

Publication Number Publication Date
CU22585A1 true CU22585A1 (es) 1999-11-03

Family

ID=5459408

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1995122A CU22585A1 (es) 1995-11-17 1995-11-17 Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.

Country Status (10)

Country Link
US (1) US6433148B1 (es)
EP (1) EP0820472A1 (es)
JP (1) JPH11505131A (es)
KR (1) KR19980701501A (es)
CN (1) CN1175958A (es)
AU (1) AU719369B2 (es)
BR (1) BR9606978A (es)
CA (1) CA2210705A1 (es)
CU (1) CU22585A1 (es)
WO (1) WO1997019113A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
WO2006102687A1 (en) * 2005-03-22 2006-09-28 The Trustees Of Columbia University In The City Of New York A liposome-based microarray and methods of use thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
ES2690542T3 (es) 2010-02-04 2018-11-21 Biomarin Pharmaceutical Inc. Método para purificar variantes de fenilalanina amoníaco-liasa procariotas
JP6404821B2 (ja) * 2013-09-12 2018-10-17 国立大学法人 岡山大学 インターロイキン１０産生促進剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01502751A (ja) * 1987-03-23 1989-09-21 ハイヴァー　リミテッド 新規ワクチン類
JP2852705B2 (ja) 1989-09-15 1999-02-03 タノックス バイオシステムズ インコーポレイテッド 自己免疫疾患の治療
US5208146A (en) * 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
ES2166770T3 (es) 1993-12-09 2002-05-01 Centro Inmunologia Molecular Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos.

Also Published As

Publication number Publication date
CN1175958A (zh) 1998-03-11
EP0820472A1 (en) 1998-01-28
US6433148B1 (en) 2002-08-13
KR19980701501A (ko) 1998-05-15
BR9606978A (pt) 1997-11-04
MX9705444A (es) 1998-06-28
CA2210705A1 (en) 1997-05-29
WO1997019113A2 (es) 1997-05-29
JPH11505131A (ja) 1999-05-18
WO1997019113A3 (es) 1997-09-25
AU7690496A (en) 1997-06-11
AU719369B2 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
Silveira et al. An outbreak of cutaneous leishmaniasis among soldiers in Belém, Pará State, Brazil, caused by Leishmania (Viannia) lindenbergi n. sp.-a new leishmanial parasite of man in the Amazon region
Low et al. Chemical characterization of thymosin beta 4.
AR005339A1 (es) Anticuerpos monoclonales antiidiotipos (ab2) y sus usos
Preble et al. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon
Greenwood et al. Evidence for a malaria mitogen in human malaria
Sugiura et al. Wheat germ agglutinin-positive cells in a stem cell-enriched fraction of mouse bone marrow have potent natural suppressor activity.
EA199700359A1 (ru) Пептиды и соединения, связывающиеся с тромбопоэтиновым рецептором
Pietraforte et al. Autoreactive T-cells in psoriasis: are they spoiled Tregs and can therapies restore their functions?
HUP9903378A2 (hu) Az autoimmun betegségek immunterápiájában felhasználható autoantigének és ezekkel szerkezetileg rokon fehérjék
DK0668772T3 (da) Specifik immunsystemmodulering
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
CU22585A1 (es) Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
DK101888A (da) Immunmodulerende midler og anvendelse af disse
Staerz et al. Use of anti-receptor antibodies to focus T-cell activity
Barnett et al. Antinuclear factors in synovia: Possible participants in the rheumatoid inclusion body
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
Kasow et al. Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX
Sharma et al. Avian cellular immunology
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
Yi et al. Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules
Mihich Immunity, Cancer, and Chemotherapy: Basic Relationship on the Cellular Level
Lopo et al. Sperm-specific surface antigenicity common to seven animal phyla
Revillard Cell-Mediated Immunity. In Vitro Correlates: Based on the 2nd International Post Graduate Course on Organ Transplantation, Lyon, May 1970
Ravindranath et al. Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E* 01: 01 and Anti-HLA-E* 01: 03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients
David H-2 antigens: genes, molecules, function